|
Gene: OSCP1 |
Gene summary for OSCP1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | OSCP1 | Gene ID | 127700 |
Gene name | organic solute carrier partner 1 | |
Gene Alias | C1orf102 | |
Cytomap | 1p34.3 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q8WVF1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
127700 | OSCP1 | C21 | Human | Oral cavity | OSCC | 4.87e-10 | 3.08e-01 | 0.2678 |
127700 | OSCP1 | C30 | Human | Oral cavity | OSCC | 6.96e-18 | 6.26e-01 | 0.3055 |
127700 | OSCP1 | C51 | Human | Oral cavity | OSCC | 4.40e-02 | 2.15e-01 | 0.2674 |
127700 | OSCP1 | SYSMH2 | Human | Oral cavity | OSCC | 1.15e-02 | 1.18e-01 | 0.2326 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | EOLP: Erosive Oral lichen planus | |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000963618 | Oral cavity | OSCC | response to toxic substance | 137/7305 | 262/18723 | 7.94e-06 | 8.52e-05 | 137 |
GO:009875418 | Oral cavity | OSCC | detoxification | 75/7305 | 152/18723 | 5.99e-03 | 2.28e-02 | 75 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
OSCP1 | SNV | Missense_Mutation | c.849N>T | p.Gln283His | p.Q283H | Q8WVF1 | protein_coding | deleterious(0.02) | benign(0) | TCGA-DI-A0WH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
OSCP1 | SNV | Missense_Mutation | novel | c.305A>G | p.Asp102Gly | p.D102G | Q8WVF1 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
OSCP1 | SNV | Missense_Mutation | novel | c.76N>T | p.Arg26Trp | p.R26W | Q8WVF1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
OSCP1 | SNV | Missense_Mutation | novel | c.61N>A | p.Leu21Ile | p.L21I | Q8WVF1 | protein_coding | deleterious(0.01) | possibly_damaging(0.785) | TCGA-4R-AA8I-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
OSCP1 | SNV | Missense_Mutation | c.281N>T | p.Gln94Leu | p.Q94L | Q8WVF1 | protein_coding | tolerated(0.14) | benign(0.216) | TCGA-ED-A7PZ-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
OSCP1 | SNV | Missense_Mutation | novel | c.387N>T | p.Leu129Phe | p.L129F | Q8WVF1 | protein_coding | deleterious(0.01) | possibly_damaging(0.718) | TCGA-49-6761-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
OSCP1 | SNV | Missense_Mutation | c.1038C>A | p.Asn346Lys | p.N346K | Q8WVF1 | protein_coding | tolerated(0.1) | benign(0.035) | TCGA-50-5049-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
OSCP1 | SNV | Missense_Mutation | c.40N>A | p.Gly14Ser | p.G14S | Q8WVF1 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-55-6984-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | chemo | PD | |
OSCP1 | SNV | Missense_Mutation | c.866N>T | p.Asn289Ile | p.N289I | Q8WVF1 | protein_coding | deleterious(0) | possibly_damaging(0.646) | TCGA-18-3421-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
OSCP1 | SNV | Missense_Mutation | novel | c.881N>T | p.Glu294Val | p.E294V | Q8WVF1 | protein_coding | deleterious(0.01) | possibly_damaging(0.626) | TCGA-68-7757-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |